Peritonitis - Pipeline Insight, 2021

This “Peritonitis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Peritonitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peritonitis Understanding

Peritonitis: Overview

Peritonitis is a redness and swelling (inflammation) of the tissue that lines your belly or abdomen. This tissue is called the peritoneum. It can be a serious, deadly disease. This condition can be caused by infectious agents, including bacteria and fungi. It is important to treat peritonitis quickly to prevent any infection from spreading to other parts of the body. Different people experience different peritonitis symptoms. The most common symptoms are: severe pain in the abdomen that gets worse when you move, nausea and vomiting, fever, abdomen that is swollen or tender to the touch, passing smaller amounts of stool or change in stool habits, and unexplained weight loss. Treatment usually involves being given antibiotics into a vein (intravenously). If a person have peritonitis caused by kidney dialysis treatment, antibiotics may be injected directly into your stomach lining.

"Peritonitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritonitis pipeline landscape is provided which includes the disease overview and Peritonitis treatment guidelines. The assessment part of the report embraces, in depth Peritonitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritonitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peritonitis R&D. The therapies under development are focused on novel approaches to treat/improve Peritonitis.

Peritonitis Emerging Drugs Chapters

This segment of the Peritonitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritonitis Emerging Drugs

Fosfomycin+metronidazole+molgramostim: Reponex Pharmaceuticals

Reponex has developed and formulated a medicinal product containing GM-CSF and two antibiotics for instillation into the peritoneal cavity at operation. Reponex's drug combination is expected to have a relevant therapeutic effect to prevent and treat peritonitis resulting from perforation of the gastrointestinal tract, e.g. perforated appendix or after bowel surgery and thereby significantly reduce hospitalization for the benefit of the patients and costs. After a successful clinical phase II acceptability and safety study, the second clinical phase II study on perforated appendix in collaboration with Herlev Hospital is in the final stage.

PD-protec: Zytoprotec

PD-protec® is being developed to prevent severe complications currently associated with peritoneal dialysis (PD). Essential ingredients of all available PD fluids, or solutions, inherently damage abdominal tissue. This is a major impediment to a more widespread use of peritoneal dialysis. PD is a cost-effective form of dialysis that patients can perform at home, at work or even while traveling. Typically, peritoneal dialysis allows them to lead more mobile and independent lives compared to hemodialysis, where patients are required to visit a treatment center for 4 to 5 hours, 3 times a week. PD-protec® is a PD solution that includes a cytoprotective compound (Alanyl-Glutamine) to protect peritoneal tissue, thus prolonging the time patients can stay on PD. The product has successfully completed Phase II clinical development. In this best-in-class Phase II trial, PD-protec® demonstrated significant improvement of important biomarkers of peritoneal membrane integrity and peritoneal immune competence, thereby confirming the potential of PD-protec® to reduce clinically important complications such as peritonitis and dialysis failure in PD.

Peritonitis: Therapeutic Assessment

This segment of the report provides insights about the different Peritonitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peritonitis

There are approx. 3+ key companies which are developing the therapies for Peritonitis. The companies which have their Peritonitis drug candidates in the most advanced stage, i.e. phase II include, Reponex Pharmaceuticals.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Peritonitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritonitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritonitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritonitis drugs.

Peritonitis Report Insights

• Peritonitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peritonitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peritonitis drugs?
• How many Peritonitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritonitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peritonitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peritonitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Reponex Pharmaceuticals
• Zytoprotec
• Cantargia
• BiomX

Key Products

• Fosfomycin+metronidazole+molgramostim
• PD-protec
• CAN 10

Research programme: bacteriophage-based therapies

This product will be delivered within 2 business days.